RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Satsuma Pharmaceuticals ROA 2024

Satsuma Pharmaceuticals ROA

-1.28

Satsuma Pharmaceuticals Dividend yield

Ticker

STSA

ISIN

US80405P1075

WKN

A2PQPD

In 2024, Satsuma Pharmaceuticals's return on assets (ROA) was -1.28, a 173.69% increase from the -0.47 ROA in the previous year.

Satsuma Pharmaceuticals Aktienanalyse

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals Inc is a young company that was founded in 2016. The company is a biotechnology company specializing in the development and commercialization of medications for the treatment of migraines. Its headquarters are located in South San Francisco, California. The business model of Satsuma Pharmaceuticals is based on the development of medications for the treatment of migraines. The company uses the latest research findings to develop more effective treatment options for patients with migraines. Migraine is one of the most common neurological disorders worldwide. It is estimated that approximately 1 billion people worldwide suffer from this disease, with women being more commonly affected than men due to hormonal differences. Satsuma Pharmaceuticals aims to combat this widespread disease by reducing the severity and frequency of migraine attacks for patients. To achieve its goals, Satsuma Pharmaceuticals has developed a technology platform that enables the development of new medications for the treatment of migraines. This platform is based on the latest developments in medication development and includes various areas such as drug research, preclinical development, clinical development, and approval processes. Satsuma Pharmaceuticals closely collaborates with leading physicians and researchers to develop its medications. The company conducts clinical trials to evaluate the effectiveness and safety of its medications and hopes to soon bring its first products to the market. Currently, Satsuma Pharmaceuticals is focused on the clinical development of a medication called STS101 for the treatment of migraines. This medication is a combination of an already established migraine medication and a new formulation technology. STS101 aims to quickly and effectively treat migraine attacks, thus improving the quality of life for patients with migraines. The company believes that STS101 represents a significant breakthrough in the treatment of migraines. Overall, Satsuma Pharmaceuticals is a promising company that has focused on combating one of the most common neurological disorders in the world. Through close collaboration with leading researchers and physicians, as well as new technology platforms, the company has the potential to make significant advancements in the development of medications for the treatment of migraines and thus improve the lives of millions of people worldwide. Satsuma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Satsuma Pharmaceuticals's Return on Assets (ROA)

Satsuma Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Satsuma Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Satsuma Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Satsuma Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Satsuma Pharmaceuticals Stock

What is the Return on Assets (ROA) of Satsuma Pharmaceuticals this year?

The Return on Assets (ROA) of Satsuma Pharmaceuticals is -1.28 undefined this year.

What was the ROA of Satsuma Pharmaceuticals compared to the previous year?

The ROA of Satsuma Pharmaceuticals has increased by 173.69% compared to the previous year.

What consequences do high ROA have for investors of Satsuma Pharmaceuticals?

A high ROA is advantageous for investors of Satsuma Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Satsuma Pharmaceuticals?

A low ROA can be unfavorable for investors of Satsuma Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Satsuma Pharmaceuticals affect the company?

An increase in ROA of Satsuma Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Satsuma Pharmaceuticals impact the company?

A reduction in the ROA of Satsuma Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Satsuma Pharmaceuticals?

Some factors that can influence the ROA of Satsuma Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Satsuma Pharmaceuticals important for investors?

The ROA of Satsuma Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Satsuma Pharmaceuticals take to improve ROA?

To improve ROA, Satsuma Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Satsuma Pharmaceuticals pay?

Over the past 12 months, Satsuma Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Satsuma Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Satsuma Pharmaceuticals?

The current dividend yield of Satsuma Pharmaceuticals is .

When does Satsuma Pharmaceuticals pay dividends?

Satsuma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, December, March, April.

How secure is the dividend of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Satsuma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Satsuma Pharmaceuticals located?

Satsuma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Satsuma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Satsuma Pharmaceuticals from 4/15/2014 amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on 3/28/2014.

When did Satsuma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/15/2014.

What was the dividend of Satsuma Pharmaceuticals in the year 2023?

In the year 2023, Satsuma Pharmaceuticals distributed 0 USD as dividends.

In which currency does Satsuma Pharmaceuticals pay out the dividend?

The dividends of Satsuma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Satsuma Pharmaceuticals

Our stock analysis for Satsuma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Satsuma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.